Key facts
- Soley Therapeutics’s last known valuation is $700.0M (Jul 2025).
- It has raised $290.0M across 1 recorded rounds; the latest was Early Stage VC ($20.0M) in Oct 2020.
- Notable investors include Breyer Capital, Artisanal Ventures, Surveyor Capital, GordonMD Global Investments, RWN Management — 10 tracked in total.
- Soley Therapeutics has filed 1 Form D with the SEC, most recently Dec 2020 ($20.0M sold to 32 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Soley Therapeutics
Funding rounds
1 roundsAbout Soley Therapeutics
Operator of a drug discovery platform intended to accelerate the development of therapies for complex diseases. The company offers an automated image-based technology using AI and machine learning to interpret cellular responses to compounds, enabling pharmaceutical and biotechnology researchers to identify drug candidates and improve decision-making across development programs.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2020
- Employees
- 39
- Website
- soleytherapeutics.com/
- Ownership
- Privately Held (backing)
Soley Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Soley Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Soley Therapeutics in its N-PORT filings yet. We sweep new filings monthly.